- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
11
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
11 companies
Merck
Market Cap: US$272.3b
Operates as a healthcare company worldwide.
MRK
US$110.03
7D
-2.2%
1Y
29.9%
Illumina
Market Cap: US$19.5b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$126.92
7D
-3.8%
1Y
64.6%
Exelixis
Market Cap: US$11.3b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.93
7D
-2.1%
1Y
16.5%
ACADIA Pharmaceuticals
Market Cap: US$3.8b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.67
7D
4.0%
1Y
57.1%
ADMA Biologics
Market Cap: US$2.5b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$10.90
7D
-0.5%
1Y
-54.2%
Aurinia Pharmaceuticals
Market Cap: US$2.1b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$16.04
7D
1.4%
1Y
97.5%
Theravance Biopharma
Market Cap: US$863.5m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.76
7D
1.1%
1Y
71.5%
CorMedix
Market Cap: US$613.3m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.57
7D
2.6%
1Y
-17.0%
Abeona Therapeutics
Market Cap: US$303.8m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.36
7D
-0.4%
1Y
1.1%
Compugen
Market Cap: US$276.1m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.73
7D
-3.9%
1Y
95.0%
Oramed Pharmaceuticals
Market Cap: US$166.2m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$4.03
7D
4.7%
1Y
73.0%